Pulmonary Function Testing (PFT) is a vital tool in respiratory medicine, offering valuable insights into lung function and capacity. However, the interpretation of PFT data can be complex, requiring a comprehensive understanding of respiratory physiology and pathophysiology. This article aims to provide healthcare professionals with a concise guide to interpreting PFT results.
The fundamental components of PFTs include spirometry, lung volumes, and diffusion capacity. Spirometry measures the volume and speed of air that can be inhaled and exhaled, providing data on FEV1 and FVC. Lung volumes, including TLC, FRC, and RV, are measured using body plethysmography or gas dilution techniques. Diffusion capacity assesses the lung's ability to transfer gases.
Abnormal PFT patterns are classified into obstructive, restrictive, or mixed disorders. Obstructive disorders, such as COPD and asthma, are characterized by reduced FEV1/FVC ratio. Restrictive disorders, like pulmonary fibrosis, show a decrease in lung volumes, particularly TLC. Mixed disorders exhibit features of both obstructive and restrictive patterns.
Interpretation of PFT should always be done in the context of the patient's clinical presentation and history. For instance, a reduced diffusion capacity in a smoker may suggest emphysema, while in a non-smoker with exertional dyspnea, it might indicate interstitial lung disease. Therefore, PFT interpretation is not only about deciphering numbers but understanding their clinical implications.
Interpreting PFT is a critical skill for healthcare professionals involved in respiratory care. A thorough understanding of the basic components, recognizing abnormal patterns, and interpreting the data in a clinical context can enhance diagnostic accuracy and patient care. Continuous learning and practice are key to mastering this complex yet indispensable tool in pulmonary medicine.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation